Christian Tiesmeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christian Tiesmeyer has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alexander V. Statsyuk
Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy
2 shared publications - Caroline Kisker
University of Würzburg
2 shared publications - Christoph Sotriffer
Institute of Pharmacy and Food Chemistry, Julius-Maximilians-Universität Würzburg
2 shared publications - Eva Altmann
Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
2 shared publications - Florian Sauer
Rudolf Virchow Center for Integrative and Translational Bioimaging, Institute for Structural Biology, Julius-Maximilians-University Würzburg, Würzburg, Germany
2 shared publications - Stefan G. Kathman
Department of Chemistry, The Scripps Research Institute, La Jolla, USA
2 shared publications
Latest Publications
- Open Access
- 8 October 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2012
Front Cover: Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis (ChemMedChem 19/2018)
- 8 October 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2012
Open AccessFront Cover: Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis (ChemMedChem 19/2018)
- 6 September 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2014-2023
Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis
Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target‐hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine‐based inhibitors identified represent the first active‐site‐directed small‐molecule inhibitors of Cdu1. High‐resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active‐site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure‐guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors.
- 6 September 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2014-2023
Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis
Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target‐hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine‐based inhibitors identified represent the first active‐site‐directed small‐molecule inhibitors of Cdu1. High‐resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active‐site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure‐guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors.